Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium Susan G. Komen for the Cure-AACR Outstanding Investigator Award for Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sapra, P.
Right arrow Articles by Allen, T. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sapra, P.
Right arrow Articles by Allen, T. M.
[Cancer Research 62, 7190-7194, December 15, 2002]
© 2002 American Association for Cancer Research

Advances in Brief

Internalizing Antibodies Are Necessary for Improved Therapeutic Efficacy of Antibody-targeted Liposomal Drugs1

Puja Sapra and Theresa M. Allen2

Department of Pharmacology, University of Alberta, Edmonton, Alberta, T6G 2H7 Canada

Direct experimental proof has been sought for the hypothesis that liposomal drugs targeted against internalizing epitopes (e.g., CD19) will have higher therapeutic efficacies than those targeted against noninternalizing epitopes (e.g., CD20). Anti-CD19-targeted liposomes were rapidly internalized into human B-lymphoma (Namalwa) cells, whereas those targeted with anti-CD20 were not internalized. Similar in vitro binding and cytotoxicity were observed for anti-CD19-targeted and anti-CD20-targeted liposomal formulations of doxorubicin (DXR). Therapeutic experiments were performed in severe combined immunodeficient mice inoculated i.v. with Namalwa cells. Administration of single i.v. doses of DXR-loaded anti-CD19-targeted liposomes resulted in significantly greater survival times than either DXR-loaded anti-CD20-targeted liposomes or nontargeted liposomes. The therapeutic advantage of targeting internalizing versus noninternalizing epitopes has been directly demonstrated.




This article has been cited by other articles:


Home page
 CA Cancer J ClinHome page
X. Wang, L. Yang, Z. Chen, and D. M. Shin
Application of Nanotechnology in Cancer Therapy and Imaging
CA Cancer J Clin, March 1, 2008; 58(2): 97 - 110.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. S. K. Sutherland, R. J. Sanderson, K. A. Gordon, J. Andreyka, C. G. Cerveny, C. Yu, T. S. Lewis, D. L. Meyer, R. F. Zabinski, S. O. Doronina, et al.
Lysosomal Trafficking and Cysteine Protease Metabolism Confer Target-specific Cytotoxicity by Peptide-linked Anti-CD30-Auristatin Conjugates
J. Biol. Chem., April 14, 2006; 281(15): 10540 - 10547.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. M. Laginha, S. Verwoert, G. J.R. Charrois, and T. M. Allen
Determination of Doxorubicin Levels in Whole Tumor and Tumor Nuclei in Murine Breast Cancer Tumors
Clin. Cancer Res., October 1, 2005; 11(19): 6944 - 6949.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Sapra, R. Stein, J. Pickett, Z. Qu, S. V. Govindan, T. M. Cardillo, H. J. Hansen, I. D. Horak, G. L. Griffiths, and D. M. Goldenberg
Anti-CD74 Antibody-Doxorubicin Conjugate, IMMU-110, in a Human Multiple Myeloma Xenograft and in Monkeys
Clin. Cancer Res., July 15, 2005; 11(14): 5257 - 5264.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. F. Kukowska-Latallo, K. A. Candido, Z. Cao, S. S. Nigavekar, I. J. Majoros, T. P. Thomas, L. P. Balogh, M. K. Khan, and J. R. Baker Jr.
Nanoparticle Targeting of Anticancer Drug Improves Therapeutic Response in Animal Model of Human Epithelial Cancer
Cancer Res., June 15, 2005; 65(12): 5317 - 5324.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. M. Allen, D. R. Mumbengegwi, and G. J.R. Charrois
Anti-CD19-Targeted Liposomal Doxorubicin Improves the Therapeutic Efficacy in Murine B-Cell Lymphoma and Ameliorates the Toxicity of Liposomes with Varying Drug Release Rates
Clin. Cancer Res., May 1, 2005; 11(9): 3567 - 3573.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
S. M. Moghimi, A. C. Hunter, and J. C. Murray
Nanomedicine: current status and future prospects
FASEB J, March 1, 2005; 19(3): 311 - 330.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C.-L. Law, C. G. Cerveny, K. A. Gordon, K. Klussman, B. J. Mixan, D. F. Chace, D. L. Meyer, S. O. Doronina, C. B. Siegall, J. A. Francisco, et al.
Efficient Elimination of B-Lineage Lymphomas by Anti-CD20-Auristatin Conjugates
Clin. Cancer Res., December 1, 2004; 10(23): 7842 - 7851.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Harata, Y. Soda, K. Tani, J. Ooi, T. Takizawa, M. Chen, Y. Bai, K. Izawa, S. Kobayashi, A. Tomonari, et al.
CD19-targeting liposomes containing imatinib efficiently kill Philadelphia chromosome-positive acute lymphoblastic leukemia cells
Blood, September 1, 2004; 104(5): 1442 - 1449.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Sapra and T. M. Allen
Improved Outcome When B-Cell Lymphoma Is Treated with Combinations of Immunoliposomal Anticancer Drugs Targeted to Both the CD19 and CD20 Epitopes
Clin. Cancer Res., April 1, 2004; 10(7): 2530 - 2537.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Sapra, E. H. Moase, J. Ma, and T. M. Allen
Improved Therapeutic Responses in a Xenograft Model of Human B Lymphoma (Namalwa) for Liposomal Vincristine versus Liposomal Doxorubicin Targeted via Anti-CD19 IgG2a or Fab' Fragments
Clin. Cancer Res., February 1, 2004; 10(3): 1100 - 1111.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Gabizon, A. T. Horowitz, D. Goren, D. Tzemach, H. Shmeeda, and S. Zalipsky
In Vivo Fate of Folate-Targeted Polyethylene-Glycol Liposomes in Tumor-Bearing Mice
Clin. Cancer Res., December 15, 2003; 9(17): 6551 - 6559.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. Pastorino, C. Brignole, D. Marimpietri, M. Cilli, C. Gambini, D. Ribatti, R. Longhi, T. M. Allen, A. Corti, and M. Ponzoni
Vascular Damage and Anti-angiogenic Effects of Tumor Vessel-Targeted Liposomal Chemotherapy
Cancer Res., November 1, 2003; 63(21): 7400 - 7409.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2002 by the American Association for Cancer Research.